Patent · US Active

Di-aliphatic substituted pegylated lipids

US9701623B2 · kind B2 · utility

1Cited by

0References

40Claims

0Family size

Assignees

Alnylam Pharmaceuticals, Inc. · US
Takeda Pharmaceutical Company Limited · JP

Inventors

Muthiah Manoharan · Carlsbad, US
Kallanthottathil G. Rajeev · Wayland, US
Jayaprakash K. Nair · Cambridge, US
Muthusamy Jayaraman · Cambridge, US
Satoru Matsumoto · Tokyo, JP

Key dates

Filing date	Sep 27, 2012
Grant date	Jul 11, 2017
Priority date	—
Expiry date	Sep 27, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to di-aliphatic substituted PEGylated lipids and to methods of their preparation. The disclosure also relates to lipid conjugates containing di-aliphatic substituted PEGylated lipids, and to the use of di-aliphatic substituted PEGylated-lipid conjugates in drug delivery.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.